Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

A Novel Hemophilia a Mouse Model Shows Expression of a Fluorescent Reporter Under the Endogenous F8 promoter in Subsets of Liver and Kidney Endothelial Cells

Paige Patterson, Radoslaw Kaczmarek, Roland W. Herzog

Blood (2024) 144 (Supplement 1): 2573.

https://doi.org/10.1182/blood-2024-207512

Published: 2024

Journal Articles

Liver Sinusoidal Endothelial Cells but Not Hepatocytes Express a Fluorescent Reporter Under the Endogenous F8 P romoter in a New Hemophilia a Mouse Model

Paige Patterson, Radoslaw Kaczmarek, Roland W. Herzog

Blood (2023) 142 (Supplement 1): 2601.

https://doi.org/10.1182/blood-2023-189020

Published: 2023

Journal Articles

Factor VIII trafficking to CD4 + T cells shapes its immunogenicity and requires several types of antigen-presenting cells

Blood (2023) 142 (3): 290–305.

https://doi.org/10.1182/blood.2022018937

Published: 2023

Includes: Multimedia, Supplemental data

Journal Articles

Key Role of Kupffer Cells in IL-1 Dependent Activation of CD8 + T Cell Responses to AAV Transgene Product in Liver

Sandeep R.P. Kumar, Moanaro Biswas, Ype P. De Jong, Roland W. Herzog

Blood (2022) 140 (Supplement 1): 4928–4929.

https://doi.org/10.1182/blood-2022-168230

Published: 2022

Journal Articles

Combination Therapy to Enable AAV Re-Dosing and Mitigate Transgene Immunity in Liver-Targeted Gene Therapy

Jyoti Rana, Sandeep RP Kumar, Maite Munoz, Kentaro Yamada, Thais Bertollini, David M Markusic, Manuela Corti, Barry J Byrne, Roland W Herzog, Moanaro Biswas

Blood (2022) 140 (Supplement 1): 311–312.

https://doi.org/10.1182/blood-2022-169848

Published: 2022

Journal Articles

Antigen Trafficking and Possibly Intrinsic Immunostimulatory Properties Shape High Immunogenicity of Factor VIII

Radoslaw Kaczmarek, Lindsey A. George, Rodney M. Camire, Roland W Herzog

Blood (2022) 140 (Supplement 1): 967–968.

https://doi.org/10.1182/blood-2022-163879

Published: 2022

Journal Articles

Oral Anti-CD3 and Bioencapsulated FVIII Therapy Exhibit Distinct Mechanisms That Suppress Inhibitor Formation in Hemophilia a

Moanaro Biswas, Thais Bertolini, Kaman So, Jyoti Rana, Sandeep R.P. Kumar, Sha Cao, Hongyu Gao, Xiaoling Xuei, Henry Daniell, Roland W. Herzog

Blood (2022) 140 (Supplement 1): 11273–11274.

https://doi.org/10.1182/blood-2022-169734

Published: 2022

Journal Articles

Immune complications and their management in inherited and acquired bleeding disorders

Valder R. Arruda, David Lillicrap, Roland W. Herzog

Blood (2022) 140 (10): 1075–1085.

https://doi.org/10.1182/blood.2022016530

Published: 2022

Journal Articles

Helper T Cell Response to Factor VIII In Vivo Requires Several Anatomically Distinct Types of Antigen Presenting Cells

Radoslaw Kaczmarek, Annie R Pineros, Matthew Carl Arvin, Thais Bertolini, Rodney M. Camire, Roland W Herzog

Blood (2021) 138 (Supplement 1): 440.

https://doi.org/10.1182/blood-2021-146059

Published: 2021

Journal Articles

Factor IX Delivery to the Skin Primes Inhibitor Formation and Sensitizes Hemophilia B Mice to Systemic Factor IX Administration

Radoslaw Kaczmarek, Thais Bertolini, Roland W Herzog, Alexandra Sherman

Blood (2021) 138 (Supplement 1): 3194.

https://doi.org/10.1182/blood-2021-154146

Published: 2021

Journal Articles

Alternative Approaches to Oral Tolerance Induction to Factor FVIII

Thais Bertolini, Moanaro Biswas, PhD, Radoslaw Kaczmarek, PhD, Henry Daniell, PhD, Roland W Herzog, PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142661

Published: 2020

Journal Articles

Revisiting the "Danger Theory": Toll-like Receptor 9 Stimulation Triggers Activation of Conventional CD8α + and Plasmacytoid Dendritic Cells En Route to Enhancing FVIII Inhibitor Formation

Radoslaw Kaczmarek, PhD, Thais Bertolini, Roland W Herzog, PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143259

Published: 2020

Journal Articles

Cross Priming of Transgene Product-Specific CD8 + T Cells in Hepatic AAV Gene Transfer Depends on IL-1 Receptor and XCR1 + Dendritic Cells but Not TLR9

Sandeep Kumar, PhD, Moanaro Biswas, PhD, Annie R Pineros, PhD, Ype P De Jong, MD, Roland W Herzog, PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142926

Published: 2020

Journal Articles

AAV Vector Dose Determines TLR9 Dependence of CD8+ T Cell Response to Transgene Product

Ning Li, Thais Bertolini, Roland W Herzog, PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-141054

Published: 2020

Journal Articles

Toll-like Receptor 9 Activation Accelerates Inhibitor Formation in Response to Factor VIII

Radoslaw Kaczmarek, Alexandra Sherman, DVM, Moanaro Biswas, PhD, Roland W Herzog, PhD

Blood (2019) 134 (Supplement_1): 1113.

https://doi.org/10.1182/blood-2019-125348

Published: 2019

Journal Articles

Update on clinical gene therapy for hemophilia

George Q. Perrin, Roland W. Herzog, David M. Markusic

Blood (2019) 133 (5): 407–414.

https://doi.org/10.1182/blood-2018-07-820720

Published: 2019

Journal Articles

Innate Immune Activation Via TLR9 May Enhance Antibody Formation Against Factors VIII and IX in Protein and Gene Therapy

Roland W Herzog, PhD, Alexandra Sherman, DVM, Brad E. Hoffman, PhD

Blood (2017) 130 (Supplement 1): 3651.

https://doi.org/10.1182/blood.V130.Suppl_1.3651.3651

Published: 2017

Journal Articles

Lettuce Plants Expressing High Levels of Factor VIII Antigen in the Chloroplast for Oral Tolerance in Hemophilia a

Roland W Herzog, PhD, Alexandra Sherman, DVM, Kwang-Chul Kwon, PhD, Wan-Jung Chang, MS, Henry Daniell, PhD

Blood (2017) 130 (Supplement 1): 362.

https://doi.org/10.1182/blood.V130.Suppl_1.362.362

Published: 2017

Journal Articles

Reprogrammed CD4 + T Cells That Express FoxP3 + Effectively Control Inhibitory Antibody Development in Hemophilic Mice

Moanaro Biswas, PhD, Veronica Kuteyeva, Roland W Herzog, PhD

Blood (2017) 130 (Supplement 1): 175.

https://doi.org/10.1182/blood.V130.Suppl_1.175.175

Published: 2017

Journal Articles

Generation of FVIII-Specific Tregs Expressing a Chimeric Antigen Receptor (CAR) to Suppress Inhibitor Development in Hemophilia a Mice

Moanaro Biswas, PhD, Todd M Brusko, PhD, Roland W Herzog, PhD

Blood (2017) 130 (Supplement 1): 176.

https://doi.org/10.1182/blood.V130.Suppl_1.176.176

Published: 2017

NARROW

A Novel Hemophilia a Mouse Model Shows Expression of a Fluorescent Reporter Under the Endogenous F8 promoter in Subsets of Liver and Kidney Endothelial Cells

Liver Sinusoidal Endothelial Cells but Not Hepatocytes Express a Fluorescent Reporter Under the Endogenous F8 P romoter in a New Hemophilia a Mouse Model

Factor VIII trafficking to CD4 + T cells shapes its immunogenicity and requires several types of antigen-presenting cells

Key Role of Kupffer Cells in IL-1 Dependent Activation of CD8 + T Cell Responses to AAV Transgene Product in Liver

Combination Therapy to Enable AAV Re-Dosing and Mitigate Transgene Immunity in Liver-Targeted Gene Therapy

Antigen Trafficking and Possibly Intrinsic Immunostimulatory Properties Shape High Immunogenicity of Factor VIII

Oral Anti-CD3 and Bioencapsulated FVIII Therapy Exhibit Distinct Mechanisms That Suppress Inhibitor Formation in Hemophilia a

Immune complications and their management in inherited and acquired bleeding disorders

Helper T Cell Response to Factor VIII In Vivo Requires Several Anatomically Distinct Types of Antigen Presenting Cells

Factor IX Delivery to the Skin Primes Inhibitor Formation and Sensitizes Hemophilia B Mice to Systemic Factor IX Administration

Alternative Approaches to Oral Tolerance Induction to Factor FVIII

Revisiting the "Danger Theory": Toll-like Receptor 9 Stimulation Triggers Activation of Conventional CD8α + and Plasmacytoid Dendritic Cells En Route to Enhancing FVIII Inhibitor Formation

Cross Priming of Transgene Product-Specific CD8 + T Cells in Hepatic AAV Gene Transfer Depends on IL-1 Receptor and XCR1 + Dendritic Cells but Not TLR9

AAV Vector Dose Determines TLR9 Dependence of CD8+ T Cell Response to Transgene Product

Toll-like Receptor 9 Activation Accelerates Inhibitor Formation in Response to Factor VIII

Update on clinical gene therapy for hemophilia

Innate Immune Activation Via TLR9 May Enhance Antibody Formation Against Factors VIII and IX in Protein and Gene Therapy

Lettuce Plants Expressing High Levels of Factor VIII Antigen in the Chloroplast for Oral Tolerance in Hemophilia a

Reprogrammed CD4 + T Cells That Express FoxP3 + Effectively Control Inhibitory Antibody Development in Hemophilic Mice

Generation of FVIII-Specific Tregs Expressing a Chimeric Antigen Receptor (CAR) to Suppress Inhibitor Development in Hemophilia a Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only